Targeting prostate cancer with the anti-PSMA scFvD2B: a theranostic promise for nuclear medicine
- 20 Downloads
Despite the significant research activity in the design and validation of new PSMA-targeting agents, prostate cancer (PCa) remains the second most common cancer in men worldwide. PSMA-specific labeled monoclonal antibodies (mAbs) demonstrated a discrete effectiveness in the clinic, but with some drawbacks due to their large size. To circumvent these problems, mAbs-derived fragments have been investigated, since they retain the high affinity of the parent mAb for the target, being also endowed with a more favorable pharmacokinetics. This review focuses on the single-chain variable fragment D2B (scFvD2B) potentiality as a new prostate-specific membrane antigen (PSMA)-specific molecular vector in nuclear medicine (NM) applications for both diagnosis and treatment of PCa.
A critical review of PubMed and Web of Science (including MEDLINE) in the early 2019 was performed, searching for research articles focusing on the application of the fragment scFvD2B and the parent antibody IgGD2B in preclinical NM.
The scFvD2B, which is derived from one of the most promising PSMA-specific mAbs, IgGD2B, has been recently investigated and labeled with Indium-111, Iodine-131, and Iodine-123. Overall, scFvD2B showed a great potential in the preclinical setting, demonstrating a promising pharmacokinetics, especially in terms of high stability and specificity, efficiently accumulating in PSMA-expressing PCa tumors.
scFvD2B seems to be a promising fragment as a molecular vector in NM applications. Nevertheless, further investigations, especially with radiometal-labeled scFvD2B, are necessary to better characterize and optimize the unique properties of this fragment, providing the basis for a rapid translation into the clinic.
KeywordsProstate-specific membrane antigen (PSMA) Prostate cancer Nuclear molecular imaging Monoclonal antibody fragments Single-chain variable fragment D2B (scFvD2B) Radiopharmaceuticals
DC: content planning, literature search and review, manuscript writing, and editing. AZ: manuscript writing. LE: manuscript writing and content planning. NS: content planning, manuscript writing, and editing.
No funds were used for this review manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
No animals or humans were involved.
- 2.Han M, Partin AW (2001) Current clinical applications of the In-capromab Pendetide scan (ProstaScint(R) scan, Cyt-356). Rev Urol 3:165–171Google Scholar
- 5.Evangelista L, Guttilla A, Zattoni F et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63:1040–1048. https://doi.org/10.1016/j.eururo.2012.09.039 CrossRefGoogle Scholar
- 9.Kim SJ, Lee SW, Ha HK (2019) Diagnostic performance of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging in newly diagnosed intermediate to high-risk prostate cancer patients: a systematic review and meta-analysis. Urol Int 102:27–36. https://doi.org/10.1159/000493169 CrossRefGoogle Scholar
- 10.Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937. https://doi.org/10.1016/j.eururo.2016.06.021 CrossRefGoogle Scholar
- 12.Liu H, Rajasekaran AK, Moy P et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055–4060Google Scholar
- 14.Calopedos RJS, Chalasani V, Asher R et al (2017) Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20:352–360. https://doi.org/10.1038/pcan.2017.23 CrossRefGoogle Scholar
- 18.Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60:5237–5243Google Scholar
- 22.Frigerio B, Benigni F, Luison E et al (2015) Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunol Lett 168:105–110. https://doi.org/10.1016/j.imlet.2015.09.012.105-110 CrossRefGoogle Scholar
- 24.Press OW, Shan D, Howell-Clark J et al (1996) Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56:2123–2129Google Scholar
- 25.Geissler F, Anderson SK, Venkatesan P et al (1992) Intracellular catabolism of radiolabeled anti-µ antibodies by malignant B-cells. Cancer Res 52:2907–2915Google Scholar